Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo
Tóm tắt
WR1065 is the free-thiol metabolite of the cytoprotective aminothiol amifostine, which is used clinically at very high doses to protect patients against toxicity induced by radiation and chemotherapy. In an earlier study we briefly reported that the aminothiol WR1065 also inhibits HIV-1 replication in phytohemagglutinin (PHA)-stimulated human T-cell blasts (TCBs) infected in culture for 2 hr before WR1065 exposure. In this study we expanded the original observations to define the dose-response curve for that inhibition, and address the question of additive effects for the combination of WR1065 plus Zidovudine (AZT). Here we also explored the effect of WR1065 on SIV by examining TCBs taken from macaques with well-established infections several months with SIV. TCBs from healthy human donors were infected for 2 hr with HIV-1, and viral replication (p24) was measured after 72 hr of incubation with or without WR1065, AZT, or both drugs. HIV-1 replication, in HIV-1-infected human TCBs, was inhibited by 50% at 13 μM WR1065, a dose at which 80% of the cells were viable. Cell cycle parameters were the same or equivalent at 0, 9.5 and 18.7 μM WR1065, showing no drug-related toxicity. Combination of AZT with WR1065 showed that AZT retained antiretroviral potency in the presence of WR1065. Cultured CD8+ T cell-depleted PHA-stimulated TCBs from Macaca mulatta monkeys chronically infected with SIV were incubated 17 days with WR1065, and viral replication (p27) and cell viability were determined. Complete inhibition (100%) of SIV replication (p27) was observed when TCBs from 3 monkeys were incubated for 17 days with 18.7 μM WR1065. A lower dose, 9.5 μM WR1065, completely inhibited SIV replication in 2 of the 3 monkeys, but cells from the third macaque, with the highest viral titer, only responded at the high WR1065 dose. The study demonstrates that WR1065 and the parent drug amifostine, the FDA-approved drug Ethyol, have antiretroviral activity. WR1065 was active against both an acute infection of HIV-1 and a chronic infection of SIV. The data suggest that the non-toxic drug amifostine may be a useful antiretroviral agent given either alone or in combination with other drugs as adjuvant therapy.
Tài liệu tham khảo
Wilson LE, Gallant JE: HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis. 2009, 48 (2): 214-221. 10.1086/595701
Stek AM: Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep. 2009, 6 (2): 68-76. 10.1007/s11904-009-0011-2
Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ: The challenge of finding a cure for HIV infection. Science. 2009, 323 (5919): 1304-1307. 10.1126/science.1165706
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008, 300 (5): 555-570. 10.1001/jama.300.5.555
Chiao SK, Romero DL, Johnson DE: Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel. 2009, 12 (1): 53-60.
Calmy A, Hirschel B, Cooper DA, Carr A: A new era of antiretroviral drug toxicity. Antivir Ther. 2009, 14 (2): 165-179.
Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I: Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003, 17 (12): 1769-1785. 10.1097/00002030-200308150-00006
Brogly SB, Ylitalo N, Mofenson LM, Oleske J, van Dyke R, Crain MJ: In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007, 21 (8): 929-938. 10.1097/QAD.0b013e3280d5a786
Foster C, Lyall H: HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008, 61 (1): 8-12. 10.1093/jac/dkm411
Grdina DJ, Dale P, Weichselbaum R: Protection against AZT-induced mutagenesis at the HGPRT locus in a human cell line by WR-151326. Int J Radiation Oncol Biol Phys. 1992, 22: 813-815.
Grdina DJ, Nagy B, Hill CK, Wells RL, Peraino C: The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis. 1985, 6 (6): 929-931. 10.1093/carcin/6.6.929
Grdina DJ, Kataoka Y, Murley JS: Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact. 2000, 16 (4): 237-279.
Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC: Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis. 1995, 16 (4): 767-774. 10.1093/carcin/16.4.767
Grdina DJ, Murley JS, Kataoka Y, Epperly W: Relationships between cytoprotection and mutation prevention by WR-1065. Mil Med. 2002, 167 (2 Suppl): 51-53.
Kataoka Y, Murley JS, Khodarev NN, Weichselbaum RR, Grdina DJ: Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int J Radiat Oncol Biol Phys. 2002, 53 (1): 180-189.
Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS: Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA. 1991, 88 (3): 986-990. 10.1073/pnas.88.3.986
Simon G, Moog C, Obert G: Effects of glutathione precursors on human immunodeficiency virus replication. Chem Biol Interact. 1994, 91 (2-3): 217-224. 10.1016/0009-2797(94)90042-6
Ho WZ, Douglas SD: Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res Hum Retroviruses. 1992, 8 (7): 1249-1253. 10.1089/aid.1992.8.1249
Kalebic T, Schein PS: Organic thiophosphate WR-151327 suppresses expression of HIV in chronically infected cells. AIDS Res Hum Retroviruses. 1994, 10 (6): 727-733. 10.1089/aid.1994.10.727
Walker DM, Kajon AE, Torres SM, Carter MM, McCash CL, Swenberg JA: WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication. Environ Mol Mutagen. 2009, 50 (6): 460-472. 10.1002/em.20482
Freshney R: Culture of Animal Cells: A Manual of Basic Technique. 1987, 117-New York.: Alan R. Liss, Inc,
Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ: CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005, 106 (10): 3524-3531. 10.1182/blood-2005-03-1243
Walker DM, Torres SM, Kajon AE, Carter MM, McCash CL, Swenberg JA: In vitro pilot studies of WR1065-mediated activity against NRTI-induced cytotoxicty and mutagenesis, and antiviral efficacy against HIV-1, influenza A and B viruses, and adenoviruses. Environmental and Molecular Mutagenesis. 2009, 50: 460-472. 10.1002/em.20482.
Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD: Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther. 2001, 297 (3): 1067-1073.
Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P: The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem. 2003, 278 (14): 11879-11887. 10.1074/jbc.M207396200
Snyder RD, Grdina DJ: Further evidence that the radioprotective aminothiol, WR- catalytically inactivates mammalian topoisomerase II. Cancer Res. 2000, 60 (5): 1186-1188.
Mann K, Hainaut P: Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene. 2005, 24 (24): 3964-3975. 10.1038/sj.onc.1208563
Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M, Delidou H: Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res. 2006, 26 (3B): 2437-2443.
Stolarska M, Mlynarski W, Zalewska-Szewczyk B, Bodalski J: Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases--a clinical study including the pharmacoeconomic analysis. Pharmacol Rep. 2006, 58 (1): 30-34.
Souid AK, Fahey RC, Dubowy RL, Newton GL, Bernstein ML: WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1999, 44 (6): 498-504. 10.1007/s002800051124
Anacak Y, Kamer S, Haydaroglu A: Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers. Pediatr Blood Cancer. 2007, 48 (5): 579-581. 10.1002/pbc.20740
Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM: A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995, 55 (18): 4069-4072.
Bachy CM, Fazenbaker CA, Kifle G, McCarthy MP, Cassatt DR: Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Oncology. 2004, 67 (3-4): 187-193. 10.1159/000081316
Mangold DJ, Huelle BK, Miller MA, Geary RS, Sanchez-Barona DO, Swynnerton NF: Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metab Dispos. 1990, 18 (3): 281-287.
Ryser HJ, Levy EM, Mandel R, DiSciullo GJ: Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA. 1994, 91 (10): 4559-4563. 10.1073/pnas.91.10.4559
Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomic M, Weiss CD: Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood. 2004, 103 (5): 1586-1594. 10.1182/blood-2003-05-1390
Arthur LO, Bess JW, Chertova EN, Rossio JL, Esser MT, Benveniste RE: Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses. 1998, 14 (Suppl 3): S311-S319.
Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Vasquez GM: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998, 72 (10): 7992-8001.